Pfizer partners with two more Flagship biotechs on obesity, cancernews2024-11-20T11:30:45+00:00November 20th, 2024|Endpoints News|
Jupiter Bioventures raises $70M fund for ‘super-early’ sciencenews2024-11-19T13:00:15+00:00November 19th, 2024|Endpoints News|
Atlas Venture targets $450M for 14th biotech venture fundnews2024-11-18T14:17:00+00:00November 18th, 2024|Endpoints News|
Novartis strikes radiopharma deal with Ratio worth up to $745Mnews2024-11-18T13:00:29+00:00November 18th, 2024|Endpoints News|
Exclusive: Athena Countouriotis’ Avenzo taps Shanghai biotech for ADC, adds new fundsnews2024-11-18T12:00:27+00:00November 18th, 2024|Endpoints News|
Scottish biotech Trogenix debuts with viral immunotherapy platform for cancernews2024-11-18T07:00:06+00:00November 18th, 2024|Endpoints News|
Ascidian CEO Michael Ehlers leaves Apple Tree Partners for MPM BioImpactnews2024-11-14T12:00:06+00:00November 14th, 2024|Endpoints News|
Metsera raises $215M for studies of GLP-1 and amylin obesity drugsnews2024-11-13T15:07:20+00:00November 13th, 2024|Endpoints News|
Exclusive: Flagship names two CEO-partners to lead Valo Health, Apriori Bionews2024-11-13T12:00:08+00:00November 13th, 2024|Endpoints News|
Alentis nabs $181M to broaden Claudin’s scope in ADCsnews2024-11-12T12:00:37+00:00November 12th, 2024|Endpoints News|
